Becton Dickinson has completed patient enrollment in its PREVENT clinical trial for Phasix Mesh, a potential first-in-class option for preventing incisional hernias. The milestone follows recent updates including new quality leadership appointments, conference appearances, and a recall-related correction notice. The stock has returned 25.36% over the past 30 days and 30.05% over 90 days, while the one-year total shareholder return is 25.37% and the three-year total shareholder return shows a decline of 7.43%. A widely followed valuation narrative puts Becton Dickinson's fair value at about $189.58, slightly below the last close of $192, implying the stock is about 1% overvalued. The company is also planning to separate its Biosciences and Diagnostic Solutions business to become a pure-play medical technology leader with over 90% of revenue from consumables.
Becton Dickinson and CompanyCompleting enrollment in the PREVENT trial for Phasix Mesh advances a potential first-in-class product for incisional hernia prevention.
